LIMR Hiring Research Assistant Are you a researcher looking for your first challenge? Do you have a background in molecular and cell biology? Do you want to further your career in one of the UK’s leading research intensive Universities? The, apply to Research Assistant in Cancer Biology at LIMR
Job Title: Research Assistant
Eligibility: Background in Molecular biology or cell biology
Location: Leeds-St James University Hospital
School/Institute: Leeds Institute of Medical Research
Salary: £30,487 to £36,024 per annum
Working type: full time
Contract type: Fixed term(available for 9 months due to external grant income)
Overview of the Research Assistant Role in Cancer Biology at LIMR:
- The project aimed at identifying the molecular mechanisms that lead to the pathogenesis of B cell-derived malignancies, including lymphomas and multiple myeloma.
- The project builds from our previous work that has identified the mechanisms of transcription factors that are often erroneously activated in B-cell tumors due to genetic mutations in the tumor-precursor cells.
- The project will aim to understand the oncogenic function of these transcription factors in the pathogenesis of non-Hodgkin lymphoma and multiple myeloma, and to identify new molecular targets for the treatment of these tumors. This is the most critical step towards the realization of precision medicine in the treatment of these currently incurable malignancies.
- The selected candidate makes use of a large spectrum of techniques, including in vitro assay systems (cell lines and primary lymphoid/tumor cells), flow cytometry, genomics approaches, and transgenic mouse models.
Possible interview questions and answers:
1. Can you describe your experience in molecular research related to B cell-derived malignancies and transcription factors?
Answer: I have a strong background in molecular research, particularly in the field of B cell-derived malignancies. My previous work has involved studying transcription factors that are aberrantly activated in these malignancies due to genetic mutations in precursor cells.
2. What specific techniques and methodologies have you used in your previous research related to oncogenic transcription factors?
Answer: In my previous research, I have utilized techniques such as chromatin immunoprecipitation (ChIP), RNA sequencing, and CRISPR/Cas9 gene editing to investigate the mechanisms of oncogenic transcription factors in B cell-derived malignancies.
3. How do you plan to approach the identification of new molecular targets for the treatment of non-Hodgkin lymphoma and multiple myeloma in this project?
Answer: I plan to employ a combination of functional genomics approaches, including high-throughput screening, to identify potential molecular targets. Additionally, I will collaborate with experts in the field to validate these targets and explore their therapeutic potential.
4.Can you explain the importance of understanding the oncogenic function of transcription factors in the context of precision medicine for these malignancies?
Answer: Understanding the oncogenic function of transcription factors is crucial because it helps us identify specific molecular vulnerabilities in these malignancies. This knowledge is essential for developing targeted therapies that can lead to more effective and precise treatments, ultimately improving patient outcomes.
5.What challenges do you anticipate in this research project, and how would you address them?
Answer: One challenge could be the complexity of the molecular pathways involved. To address this, I would collaborate with multidisciplinary teams and leverage advanced computational tools for data analysis. Additionally, I would stay updated on the latest research findings in the field.
6. Can you describe your experience with collaborating on research projects, especially with interdisciplinary teams?
Answer: I have a track record of successful collaboration with interdisciplinary teams, including geneticists, bioinformaticians, and clinicians. Effective communication and a shared commitment to the project’s goals are key to successful collaboration.
7. What is your familiarity with current advances in precision medicine and targeted therapies for B cell-derived malignancies?
Answer: I closely follow the latest developments in precision medicine and targeted therapies. Staying informed about emerging treatments and technologies is essential to ensure that our research remains cutting-edge.
8. How do you plan to ensure the ethical conduct of research, especially when working with human samples or sensitive data?
Answer: Ethical conduct is of utmost importance. I am committed to obtaining all necessary approvals and adhering to ethical guidelines. I would also ensure the privacy and informed consent of individuals involved in the research.
9. Can you provide an example of a research project where you faced unexpected results or challenges and how you adapted to them?
Answer: In a previous project, unexpected results led us to reevaluate our hypothesis. We adjusted our experimental approach, consulted with colleagues, and eventually discovered a novel mechanism that significantly advanced our understanding of the subject.
10. What motivates you to work on a project that aims to find treatments for currently incurable malignancies?
Answer: The opportunity to make a meaningful impact on patients’ lives is my primary motivation. I believe that with dedication and innovative research, we can unlock new therapeutic avenues that have the potential to transform the prognosis and treatment options for these malignancies.
LIMR Hiring Research Assistant